DMAA DRUGS MADE IN AMER ACQUTN CO revenue, earnings and financials
For the quarter ended June 30, 2026, DRUGS MADE IN AMER ACQUTN CO reported revenue of n/a, net income of $1.73M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was n/a.
DMAA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$2.82M, net income $5.94M (margin n/a), EPS n/a
DMAA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income $1.73M, EPS n/a
- Quarter ended Mar 31, 2026: revenue n/a, net income $1.97M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $213K, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income $2.18M, EPS n/a
- Quarter ended Jun 30, 2025: revenue n/a, net income $2.29M, EPS n/a
- Quarter ended Mar 31, 2025: revenue n/a, net income $1.25M, EPS n/a
- Quarter ended Sep 30, 2024: revenue n/a, net income −$145K, EPS n/a
DMAA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$539K, share buybacks n/a
DMAA balance sheet
- Jun 30, 2026: cash $20.3K, total assets $147M, total liabilities $9.14M, shareholders' equity −$7.41M
- Mar 31, 2026: cash $14.9K, total assets $242M, total liabilities $7.39M, shareholders' equity −$7.38M
- Dec 31, 2025: cash $6.14K, total assets $240M, total liabilities $7.28M, shareholders' equity −$7.26M
- Sep 30, 2025: cash n/a, total assets $238M, total liabilities $7.36M, shareholders' equity −$7.33M
- Jun 30, 2025: cash n/a, total assets $235M, total liabilities $7.20M, shareholders' equity −$7.15M
- Mar 31, 2025: cash n/a, total assets $233M, total liabilities $7.25M, shareholders' equity −$7.18M
- Dec 31, 2024: cash n/a, total assets $551K, total liabilities $796K, shareholders' equity −$245K
Is DMAA profitable?
Yes. DRUGS MADE IN AMER ACQUTN CO earned $6.09M over the last four quarters.